FGF-2 Polyclonal Antibody
¥680.00
- 产品信息
商品描述
靶点-Target
PCNA
反应性
Human,Rat,Mouse
应用
WB,IF,IHC
宿主物种-Host Species
Mouse
同种型-Isotype
IgG1
偶联-Conjugate
HRP
修饰-Modification
Unmodified
MW(Observed)
30-33kD
推荐稀释比
Optimal working dilutions should be determined experimentally by the investigator;Suggested starting dilutions are as follows:WB 1:5000;IHC 1:200.
组成
Liquid in PBS, pH 7.4, containing 0.02% sodium azide as preservative and 50% Glycerol.
纯化工艺
The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
储存
Stable for one year at -15°C to -25°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
浓度
1mg/ml
克隆性
Monoclonal
克隆号
12D10
特异性
PCNA Monoclonal Antibody(12D10) HRP Conjugated, specially designed for your Western blot analysis.
基因名称
PCNA
蛋白名称
Proliferating cell nuclear antigen
别名
PCNA;Proliferating cell nuclear antigen;PCNA;Cyclin
Organism-1
Human
基因ID-1
5111
SwissProt-1
P12004
背景
The protein encoded by this gene is found in the nucleus and is a cofactor of DNA polymerase delta. The encoded protein acts as a homotrimer and helps increase the processivity of leading strand synthesis during DNA replication. In response to DNA damage, this protein is ubiquitinated and is involved in the RAD6-dependent DNA repair pathway. Two transcript variants encoding the same protein have been found for this gene. Pseudogenes of this gene have been described on chromosome 4 and on the X chromosome. [provided by RefSeq, Jul 2008],
细胞定位
Nucleus . Colocalizes with CREBBP, EP300 and POLD1 to sites of DNA damage (PubMed:24939902). Forms nuclear foci representing sites of ongoing DNA replication and vary in morphology and number during S phase (PubMed:15543136). Co-localizes with SMARCA5/SNF2H and BAZ1B/WSTF at replication foci during S phase (PubMed:15543136). Together with APEX2, is redistributed in discrete nuclear foci in presence of oxidative DNA damaging agents. .
